Marea Therapeutics, a subsidiary of Lisata Therapeutics, will present Phase 2b data from its lead drug candidate MAR001 at the American Heart Association Scientific Sessions 2026. MAR001 is an experimental antibody targeting ANGPTL4 to lower triglycerides and improve fat metabolism, aiming to treat severe hypertriglyceridemia. The drug has shown promising results in earlier trials, and the presentation is scheduled for November 9 in Chicago. Marea is also developing other candidates, including MAR005 for Phase 3 and MAR002 for acromegaly.
Marea Therapeutics, a Lisata subsidiary, is presenting new drug data at AHA Scientific Sessions 2026. For readers following the health sector, here is Pluang's market snapshot as of Sep 24, 2026 19:31 WIB: 40 of 100 priced health-sector US stocks rose while 55 fell. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.30 with a 3.06% increase and BioNano Genomics Inc (BNGO) at USD 1.74 with a 2.35% increase.
Bernstein upgraded Dollar General to "Outperform" due to its strategic initiatives targeting budget shoppers and expanding seasonal product offerings, especially affordable toys. The company is also growing its DG Media Network, which generates signi...
TD SYNNEX reported quarterly earnings per share of $5.68, surpassing analyst estimates of $4.70 by 22.41%, and revenue of $21.56 billion, beating estimates by 14.81%. This strong performance reflects a 37.7% revenue increase year-over-year, driving t...
Cintas reported a 10.9% revenue increase to $3.01 billion in Q1 fiscal 2027 and exceeded EPS expectations with $1.39 per share. Following this strong performance, investment firm Robert W. Baird raised its price target for Cintas to $222, implying a ...
Darden Restaurants reported Q1 2027 earnings per share of $2.05, meeting analyst expectations but down from $2.19 last year due to higher expenses. Total revenue was $3.20 billion, just below the $3.21 billion estimate. Despite this, the company saw ...
Jefferies Financial Group is expected to report a third-quarter revenue of $2.21 billion, marking an 8.1% increase year-over-year, signaling strong sales growth. However, earnings per share (EPS) are forecasted to decline slightly by 1% to around $1....
